Multiple uses of tumor necrosis therapy (TNT) for the treatment and imaging of solid tumors: Preclinical considerations and progress

2006 ◽  
Vol 1 (1) ◽  
pp. 33-47 ◽  
Author(s):  
Leslie A. Khawli ◽  
Peisheng Hu ◽  
Alan L. Epstein
Keyword(s):  
Solid Tumors ◽  
Tumor Necrosis ◽  
Tumor Necrosis Therapy ◽  
Multiple Uses

Company News

2001 ◽  
Vol 05 (13) ◽  
pp. 259-269
Keyword(s):  
Combinatorial Chemistry ◽  
Blood Test ◽  
Tumor Necrosis ◽  
Generic Version ◽  
Mainland China ◽  
Cancer Drug ◽  
Fda Approval ◽  
Tumor Necrosis Therapy ◽  
Us Fda ◽  
Medical Glass

US-based Peregrine to Continue With Tumor Necrosis Therapy in China. CardioDynamics' Proprietary Technology Available in Taiwan. Gilead Initiates Phase I Clinical Trial for Hepatitis B Drug in China. China's Medical Glass Manufacturer Imports Production Line from US-based EM. Japan's Kyowa Hakko Aims to be Top Bio-pharmaceutical Company by 2010. Australian Biotech Company Invests US$2.65 million in US Firm. Qugen — Singapore's First Gene Therapy Company. Roche Launches Cancer Drug in Japan. ChemBridge Corporation Forms Combinatorial Chemistry Alliance with Sumitomo Pharmaceuticals. Indian Pharma Company Receives US FDA Approval for Pentoxifyline. Dr. Reddy's to Launch Generic Version of Prisolec in US. US Patent Granted for Heparanese Gene. Taiwan Tobacco and Wine Board to Collaborate with Mainland China. Taiwan Company Develops Rapid Blood Test for Enterovirus. Ranbaxy Laboratories: An Update.

Tumor necrosis factor inhibitors and acute leukemia in two cases.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e18010-e18010
Author(s):  
Mehmet Ozen ◽  
Onur Keskin ◽  
Orhan Kucuksahin ◽  
Ufuk Ilgen ◽  
Pervin Topcuoglu ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Tumor Necrosis Factor ◽  
Crohn's Disease ◽  
Acute Leukemia ◽  
Natural Killer ◽  
Solid Tumors ◽  
Tumor Necrosis ◽  
Tnf Inhibitors ◽  
Killer Activity ◽  
Necrosis Factor

e18010 Background: Inhibitors of tumor necrosis factor alpha (anti-TNF agents) are commonly used in Crohn’s disease and rheumatoid arthritis. Relationship between TNF inhibitors and development of malignancy, e.g., lymphoma and solid tumors, is defined recently. However, a few authors reported leukemia. Crohn’s disease and also azothioprine may also be associated with leukemia. Here, we are presenting two acute myeloid leukemia (AML) cases using azothioprine and anti-TNF inhibitors for Crohn’s disease. Methods: Observational case report. Results: Case 1: A 56-year-old male patient with active Crohn’s disease for 4 years was refractory to first line mesalazine, corticosteroid and azothioprine treatment. So, anti-TNF monoclonal antibody (moAb) (Adalimumab) had been given. After second dose of adalimumab treatment AML (AML-M2 as FAB) developed. Case 2: A 38-year-old male had been diagnosed with ankylosing spondylitis for 7 years and Crohn’s disease for 2 years. He had been treated with salazopyrin and indomethacin. Anti-TNF etanercept (50 mg/wk) was started 30 months ago due to severe active pulmonary disease. After 1 year, he developed active Crohn’s disease. So, the treatment changed to infliximab. Also, mesalazine and azothioprine were added to treatment. On the 18th month of the infliximab t(15;17) positive acute promyelocytic leukemia were developed in the patient. Conclusions: Blocking TNF with anti TNF agents may cause blocking apoptosis and inhibit natural killer activity. So, antitumoral activity of natural killer cells is blocked by these agents. TNF alpha gene mutation has been associated with CLL, lymphoma, myelodysplastic syndrome and secondary AML. Azothioprine may also increase leukemia, lymphoma and solid tumors risk at patient on anti TNF treatment. Following the diagnosis of Crohn’s disease without immunomodulator treatment a case had developed acute leukemia in the literature. In our patients, anti-TNF, azothioprine and inflammatory bowel disease may be cause acute leukemia cumulatively. Physicians should be careful and regularly check the patients using anti-TNF agents in considering of malignancy development. In conclusion, the pathogenesis of leukemia development after TNF blockage should be clarified.

Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study.

1993 ◽  
Vol 11 (11) ◽  
pp. 2205-2210 ◽  
Author(s):  
W L Furman ◽  
D Strother ◽  
K McClain ◽  
B Bell ◽  
B Leventhal ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Phase I ◽  
Solid Tumors ◽  
Tumor Necrosis ◽  
Human Tumor ◽  
Rest Period ◽  
Supplemental Oxygen ◽  
Maximum Tolerated Dose ◽  
Human Tumor Necrosis Factor ◽  
Necrosis Factor

PURPOSE A phase I study was undertaken to determine the toxicity and maximum-tolerated dose (MTD) of recombinant human tumor necrosis factor (rTNF) in children. PATIENTS AND METHODS Twenty-seven patients with recurrent or refractory solid tumors were enrolled on the study. rTNF was administered daily for 5 days by 30-minute intravenous (IV) infusion, and doses were escalated in cohorts of three to six patients. Courses were repeated after a 9-day rest period, if toxicity was tolerable. Daily doses ranged from 100 to 350 micrograms/m2. RESULTS Most courses were associated with grade I/II fever, rigors, nausea, or vomiting. Three patients experienced moderate dyspnea that responded to supplemental oxygen. All abnormalities resolved on discontinuation of the infusion. One patient had a cardiac arrest 90 minutes after receiving the first dose of rTNF and died 10 days later of related complications. In two other patients, rTNF was discontinued due to persistent grade IV hypotension. Toxicities were not consistently related to dose and no cumulative effects were noted. The dose-limiting toxicity was transient hepatic dysfunction, which occurred in three of six patients receiving 350 micrograms/m2; this toxicity was rapidly reversed on discontinuation of the rTNF. One patient, whose non-Hodgkin's lymphoma had recurred after bone marrow transplantation, had a partial response. Disease was stabilized in two patients. CONCLUSION We recommend that phase II testing proceed at a dose of 300 micrograms/m2/d on the schedule described.

Mycobacterial Disease In Rheumatoid Arthritis Patients Who Use Anti-tumor Necrosis Therapy

2010 ◽  
Author(s):  
Kevin L. Winthrop ◽  
Roger Baxter ◽  
Liyan Liu ◽  
Bentson McFarland ◽  
Donald Austin ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis ◽  
Mycobacterial Disease ◽  
Tumor Necrosis Therapy
Sign in / Sign up

Export Citation Format

Share Document